MELBOURNE, AUSTRALIA--(MARKET WIRE)--Jun 14, 2007 -- Living Cell Technologies Ltd. (ASX:LCT.AX - News), a leading developer of live cell therapy products to treat life threatening human diseases, announced today that it has successfully dosed its first patient in a Phase I/IIa clinical trial using its proprietary DiabeCell® pig islet cell transplant to treat type I diabetes.
